US · BCPC · CHEMICALS - SPECIALTY
Balchem Corp (BCPC) intrinsic value and stock valuation
$163.54as of 2026-11-21 · Mkt cap 5.74B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Balchem Corp DCF and intrinsic value
InvestorsCraft values BCPC with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from BCPC’s statements →
Balchem Corp Graham Number
Graham Number: $64.19d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Element Solutions Inc (ESI) $29.52
- Axalta Coating Systems Ltd. (AXTA) $34.12
- Eldorado Gold Corporation (EGO) $24.75
- Sasol Limited (SSL) $11.52
- SSR Mining Inc. (SSRM) $21.59
- Perimeter Solutions, Inc. (PRM) $27.55
- Sensient Technologies Corporation (SXT) $113.85
- Cabot Corp. (CBT) $70.48
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.04B | $953.7M | $922.4M | $942.4M | $799M |
| Operating income | $218.3M | $182.9M | $159.2M | $145.2M | $127.5M |
| Net income | $154.8M | $128.5M | $108.5M | $105.4M | $96.1M |
| EPSd | $4.75M | $3.93M | $3.34M | $3.25M | $2.94M |
| Operating cash flow | $216.6M | $182M | $183.8M | $138.5M | $160.5M |
| Capital expenditure | -$-43.49M | -$-35.66M | -$-37.89M | -$-50.29M | -$-37.45M |
| Free cash flow | $173.1M | $146.3M | $145.9M | $88.3M | $123.1M |
| Total assets | $1.71B | $1.58B | $1.6B | $1.62B | $1.2B |
| Total debt | $192M | $208M | $330.3M | $460.6M | $118M |
| Net debt | $117.4M | $158.5M | $265.9M | $394.1M | $14.8M |
| Total equity | $1.26B | $1.15B | $1.05B | $938.3M | $877M |
| Cash and short-term investments | $74.6M | $49.5M | $64.5M | $66.6M | $103.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.04B | $953.7M | $922.4M | $942.4M | $799M |
| Cost of revenue | $666.5M | $617.5M | $620.4M | $661.9M | $555.9M |
| Gross profit | $370.6M | $336.2M | $302.1M | $280.5M | $243.2M |
| Research and development expenses | $18.5M | $16.8M | $15.1M | $12.2M | $13.5M |
| Selling, general and administrative expenses | $142.8M | $136.5M | $130.1M | $123.1M | $102.2M |
| Other expenses | -$-9.01M | $0.00 | -$-2.32M | $0.00 | $0.00 |
| Operating expenses | $152.3M | $153.3M | $142.9M | $135.3M | $115.7M |
| Cost and expenses | $818.8M | $770.8M | $763.3M | $797.2M | $671.5M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $10.2M | $16.5M | $22.6M | $10.3M | $2.46M |
| Depreciation and amortization | $45.2M | $48M | $54.9M | $51.9M | $48.9M |
| Ebitda | $254.4M | $231M | $214.8M | $195.9M | $176.6M |
| Operating income | $218.3M | $182.9M | $159.2M | $145.2M | $127.5M |
| Total other income/expenses, net | -$-19.3M | -$-16.46M | -$-21.93M | -$-11.44M | -$-2.27M |
| Income before tax | $199M | $166.5M | $137.3M | $133.8M | $125.2M |
| Income tax expense | $44.2M | $38M | $28.7M | $28.4M | $29.1M |
| Net income | $154.8M | $128.5M | $108.5M | $105.4M | $96.1M |
| Weighted average shares outstanding | $32.6M | $32.3M | $32.1M | $32M | $32.2M |
| Weighted average diluted shares outstanding | $32.6M | $32.7M | $32.5M | $32.4M | $32.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $74.6M | $49.5M | $64.5M | $66.6M | $103.2M |
| Net receivables | $143.6M | $119.7M | $125.3M | $131.6M | $117.4M |
| Inventory | $131.5M | $130.8M | $109.5M | $119.7M | $91.1M |
| Total current assets | $365.6M | $313.8M | $314.2M | $335.8M | $322.2M |
| Property, plant and equipment, net | $322.8M | $299.2M | $295.9M | $290.8M | $246.8M |
| Goodwill and intangible assets | $979.7M | $945.1M | $970.1M | $982.8M | $618.6M |
| Long-term investments | $3.72M | $3.86M | $4.08M | $4.29M | -$-46.45M |
| Total non-current assets | $1.34B | $1.26B | $1.28B | $1.29B | $877.1M |
| Total assets | $1.71B | $1.58B | $1.6B | $1.62B | $1.2B |
| Accounts payable | $60.4M | $54.7M | $55.5M | $57.3M | $56.2M |
| Short-term debt | $3.82M | $3.33M | $4.22M | $4.02M | $2.36M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $176.4M | $157.7M | $148.5M | $140M | $143.8M |
| Long-term debt | $188.2M | $204.7M | $326.1M | $456.6M | $115.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $273.8M | $267.8M | $394.7M | $546.2M | $178.5M |
| Capital lease obligations | $12.9M | $18M | $20.8M | $20M | $9.47M |
| Total liabilities | $450.2M | $425.5M | $543.2M | $686.2M | $322.3M |
| Common stock | $2.14M | $2.17M | $2.15M | $2.15M | $2.15M |
| Retained earnings | $1.12B | $997.5M | $897.5M | $814.5M | $732.1M |
| Accumulated other comprehensive income (loss) | $41.6M | -$-23.75M | $8.69M | -$-7.15M | -$-4.99M |
| Total equity | $1.26B | $1.15B | $1.05B | $938.3M | $877M |
| Total investments | $3.72M | $3.86M | $4.08M | $4.29M | -$-46.45M |
| Total debt | $192M | $208M | $330.3M | $460.6M | $118M |
| Net debt | $117.4M | $158.5M | $265.9M | $394.1M | $14.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $154.8M | $128.5M | $108.5M | $105.4M | $96.1M |
| Depreciation and amortization | $45.7M | $48M | $54.9M | $51.9M | $48.9M |
| Stock-based compensation | $18.1M | $16.7M | $16.1M | $13.2M | $10.8M |
| Change in working capital | -$-7.46M | -$-6.12M | $20M | -$-25.22M | $10.9M |
| Accounts receivable | -$-20.85M | $5.58M | $6.97M | -$-3.62M | -$-20.7M |
| Inventory | $3.63M | -$-22.79M | $10.5M | -$-7.8M | -$-21.02M |
| Accounts payable | $11.3M | $9.06M | $3.55M | -$-15.54M | $46.2M |
| Net cash provided by operating activities | $216.6M | $182M | $183.8M | $138.5M | $160.5M |
| Investments in property, plant and equipment | -$-43.49M | -$-35.66M | -$-37.89M | -$-50.29M | -$-37.45M |
| Acquisitions, net | -$-50K | -$-24.16M | -$-1.54M | -$-365.78M | $320K |
| Net cash used for investing activities | -$-43.89M | -$-59.74M | -$-34.81M | -$-416.01M | -$-35.3M |
| Common stock issued | $9.31M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-107.64M | -$-5.68M | -$-4.47M | -$-35.42M | -$-35.24M |
| Dividends paid | -$-28.29M | -$-25.58M | -$-22.87M | -$-20.71M | -$-18.72M |
| Net cash used for financing activities | -$-152.81M | -$-133.81M | -$-153.32M | $246.7M | -$-102.18M |
| Net change in cash | $25.1M | -$-14.93M | -$-2.11M | -$-36.68M | $18.7M |
| Cash at end of period | $74.6M | $49.5M | $64.5M | $66.6M | $103.2M |
| Operating cash flow | $216.6M | $182M | $183.8M | $138.5M | $160.5M |
| Capital expenditure | -$-43.49M | -$-35.66M | -$-37.89M | -$-50.29M | -$-37.45M |
| Free cash flow | $173.1M | $146.3M | $145.9M | $88.3M | $123.1M |
Line items
Line items
Line items
About Balchem Corp
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
- CEO
- Theodore L. Harris
- Employees
- 1.35K
- Beta
- 0.81
Included in
Explore
Frequently asked questions
What is the intrinsic value of Balchem Corp (BCPC)?
Balchem Corp (BCPC) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BCPC undervalued?
BCPC trades at a price of $163.54 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.